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Current recommendations for laboratory-based screening tests 
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Health screening tests greatly impact the public's health because they involve testing of 
asymptomatic populations for specific diseases or health conditions for which specific 
interventions may alter disease progression before appearance of clinical signs and 
symptoms. The following criteria characterize an effective screening program:1
• The screening test has acceptable performance specifications (positive and negative 
predictive values) for the disease in question
• The disease is a significant condition with major health and societal implications
• Acceptable, feasible and effective tests for presence of the disease and treatments 
are available
• Following screening, strategy to decide which patients to treat; those treated must 
be more likely to do better than those treated later when signs and symptoms 
appear in the absence of screening
• There must be a net benefit to the individual being screened for the disease while 
also considering the societal context
• The screening test is available, cost-effective and acceptable for the target 
population
• Informed consent and patient confidentiality must be ensured.
In this article, recommendations of the U.S. Preventive Services Task Force (USPSTF) for 
selected laboratory-based screening tests are described. These screening tests include those 
for colorectal cancer, cardiovascular disease risk, hepatitis C virus (HCV) infection, human 
immunodeficiency virus (HIV) infection, syphilis infection, Type 2 diabetes mellitus, and 
prostate cancer. Additionally, specific CDC recommendations, are noted when applicable.
The USPSTF, supported by the Agency for Healthcare Research and Quality, is widely 
considered to be the leading independent panel of experts in recommendations about disease 
prevention and in primary and secondary interventions. The USPSTF conducts rigorous and 
impartial assessments of the scientific evidence for effectiveness of a broad range of clinical 
preventive services.
The statements made in this article are those of the author, and they do not necessarily represent the official position of the CDC.
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Evidence is evaluated using a rating scale: “A” (strong recommendation for screening), “B” 
(recommendation for screening), “C” (recommendation neither for nor against screening), 
“D” (recommendation against screening), or “I” (inadequate or insufficient evidence to 
recommend for or against screening). Table 1 lists the USPSTF screening recommendations 
for 19 diseases or conditions in adult men. Screening for six of these diseases or conditions 
received a rating of either A or B, while seven diseases or conditions received a rating of D. 
The USPSTF's recommendations for the six diseases or condition receiving a rating of either 
A or B will be discussed in more detail. Also discussed will be the recent USPSTF rating of 
D for screening of prostate cancer.
Colorectal Cancer
Screening for colorectal cancer using fecal occult blood testing (FOBT), sigmoidoscopy or 
colonoscopy in adult men and women is strongly recommended beginning at age 50 years 
and continuing until 75 years of age (A).2 One of the following three screening methods 
may be used:
Annual, high-sensitivity FOBT High-sensitivity FOBT every 3 years plus sigmoidoscopy 
every 5 years Screening colonoscopy every 10 years
The long preclinical phase from development of adenomas to colorectal carcinoma provides 
opportunities for successful screening, diagnosis, intervention, treatment and extended lives. 
However, routine screening in asymptomatic adults 75-85 years of age (B) and screening in 
asymptomatic adults older than 85 years of age with prior history of adequate screening is 
not recommended since there is at least moderate evidence that net benefit is small (C). 
There is adequate evidence that the benefits associated with detection and early intervention 
decline after age 75 years. The lead time between detection and treatment of colorectal 
cancer and a mortality benefit is substantial, but competing causes of mortality in this 
renders it less that this benefit will be realized with advancing age.
Risk of Cardiovascular Disease
Screening men aged 35 years or older for lipid disorders up to every five years is strongly 
recommended (A); screening men aged 20-34 years for lipid disorders up to every five years 
is recommended if they are also at increased risk for coronary heart disease (CHD) 
(diabetes, previous personal or family history, tobacco use, hypertension, obesity) (B).3 
Good-quality evidence indicates that total cholesterol, LDL-cholesterol, and HDL- 
cholesterol are independent predictors of CHD risk, and ratios of total cholesterol to HDL-
cholesterol or LDL-cholesterol to HDL-cholesterol classify risk better than total cholesterol 
alone. Although triglycerides level is a strong univariate predictor of coronary events, its 
association with CHD events is reduced substantially by adjustment for other risk factors. At 
least two serum lipid measurements are necessary to ensure that true values are within 10% 
of the average of measurements.
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HCV Infection
Screening for HCV infection is recommended in adults at high risk including those with any 
history of intravenous drug use or blood transfusions prior to 1992 (B).4 Other risk factors 
include chronic hemodialysis, being born to an HCV-infected mother, imprisonment and 
intranasal cocaine and other non-injection drug use.5 The CDC recommends one-time 
testing without prior ascertainment of HCV risk for adults born between 1945 and 1965, a 
population with a disproportionately high prevalence of HCV infection and related disease.6 
The USPSTF concluded that benefit of screening all adults in this age group is small (C).4 
Anti-HCV antibody testing with subsequent polymerase chain reaction testing for viremia is 
accurate for identifying patients with chronic HCV infection.4
HIV Infection
Screening adolescents and adults aged 15-65 years for HIV infection as well as older adults 
with increased risk is recommended using repeated enzyme immunoassay for anti-HIV 
antibodies when the first test is positive, followed by confirmatory Western blot or 
immunofluorescence assay (A).7 There is convincing evidence that identification and 
treatment of HIV infection is associated with markedly reduced risk for progression to 
AIDS, AIDS-related events, and death. Overall benefits of screening for HIV infection in 
adolescents and adults are substantial with convincing evidence that use of antiretroviral 
therapy is associated with a substantially decreased risk for transmission from HIV-positive 
persons to uninfected heterosexual partners.7 The CDC recommends at least annual 
screening of all who are at high risk for HIV infection including those initiating treatment 
for tuberculosis and persons seeking treatment for sexually transmitted diseases, as well as 
one-time screening of all persons 13-64 years of age.8
Syphilis Infection
Screening persons at increased risk for syphilis infection is strongly recommended (A).9 
Populations at increased risk for syphilis infection are determined by incident rates and 
include men who have sex with men or who engage in high-risk sexual behavior, 
commercial sex workers, persons who exchange sex for drugs, and those in adult 
correctional facilities. There is adequate evidence that screening tests can accurately detect 
syphilis infection and that antibiotics can cure syphilis. These include nontreponemal tests 
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commonly used for initial screening (VDRL or RPR), followed by a confirmatory 
fluorescent treponemal antibody absorbed or T. pallidum particle agglutination test. The 
benefits of screening persons at increased risk for syphilis infection substantially outweigh 
potential harms.9
Type 2 Diabetes Mellitus
Screening for type 2 diabetes every three years in asymptomatic adults with sustained blood 
pressure (either treated or untreated) of greater than 135/80 mm Hg is recommended (B).10 
The USPSTF found adequate evidence that in adults with hypertension and diabetes, 
lowering their blood pressure below conventional target values reduces incidence of 
cardiovascular events and mortality. In addition to criteria for plasma or blood glucose 
measurement, diabetes can be diagnosed by demonstrating increased blood hemoglobin A1c 
concentrations.11 Monitoring of glycemic control may be performed by self-monitoring 
blood glucose with glucose meters and laboratory analysis of hemoglobin A1c.
Prostate Cancer
Screening for prostate cancer by testing for prostate-specific antigen (PSA) is not 
recommended (D).12 Although the precise, long-term effect of PSA screening on prostate 
cancer-specific mortality remains uncertain, existing studies adequately demonstrate that the 
reduction in prostate cancer mortality after 10-14 years is very small even for men in the 
optimal age range of 55-69 years because there is no apparent reduction in all-cause 
mortality.12 In contrast, harms associated with diagnosis and treatment of screening-detected 
cancer are common, occur early, may be persistent, and include a small but real risk for 
premature death. More men will experience harms of screening and treatment for screening-
detected asymptomatic or subclinical disease than will experience direct benefit. The over-
diagnosis and over-treatment of prostate cancer as a result of screening exposes many men 
to the adverse effects of diagnosis and treatment without increased survival. Assessing the 
balance of benefits and harms requires weighing a moderate to high probability of early and 
persistent harm from treatment against the very low probability of preventing a death from 
prostate cancer in the long term. The USPSTF has, therefore, concluded that there is 
moderate certainty that harms of PSA-based screening for prostate cancer outweigh any 
potential benefits.12
It is perhaps useful to note that outcomes for patients undergoing health screening for 
chronic diseases can be divided into several categories:1
• Those with disease which would have been cured by treatment even if it had not 
been detected by screening; in these cases, lives may not be improved by screening 
but earlier detection may impact transmission of diseases
• Those with incurable disease at the time of screening for whom screening itself 
may not change treatment or outcome but results may impact family, reproductive, 
and other decisions as well as transmission of some diseases
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• Those dying of co-morbidities other than the screened disease; the quality of life 
may actually be reduced by screening-mediated diagnostic and treatment 
interventions
• Those who are the main beneficiaries of a screening program with diseases which 
may be cured through screening and early detection
• Those who do not have the disease or condition being screened, usually the largest 
group. Harms for this group are usually minimal unless morbidity and mortality 
resulting from screening is significant.
Screening tests have individual and public health implications. The decision to participate in 
screening can be a matter of individual choice particularly for diseases or conditions with 
screening recommendation of C or I. This choice may hinge on the probability of various 
outcomes and may depend on cost of screening and access to it, as well as how individuals 
feel about them. Screening may save a few lives and reduce morbidity from progressive 
disease. A few people may experience disease-specific morbidities and eventually die of the 
disease anyway. More may face subsequent cascades of diagnostic testing or disease 
monitoring procedures with uncertainties about presence of the disease. Some may be 
treated unnecessarily or experience the morbidities (and possibly mortality) resulting from 
the treatment. In short, in some cases, whether or not to be screened may be a matter of 
personal choice.
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